PE20160891A1 - Moduladores de ror gamma (rory) - Google Patents

Moduladores de ror gamma (rory)

Info

Publication number
PE20160891A1
PE20160891A1 PE2016000733A PE2016000733A PE20160891A1 PE 20160891 A1 PE20160891 A1 PE 20160891A1 PE 2016000733 A PE2016000733 A PE 2016000733A PE 2016000733 A PE2016000733 A PE 2016000733A PE 20160891 A1 PE20160891 A1 PE 20160891A1
Authority
PE
Peru
Prior art keywords
phenyl
rory
ror gamma
alkyl
compounds
Prior art date
Application number
PE2016000733A
Other languages
English (en)
Spanish (es)
Inventor
Sander Bernardus Nabuurs
Joseph Maria Gerardus Barbara Cals
Original Assignee
Lead Pharma Cel Models Ip B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Pharma Cel Models Ip B V filed Critical Lead Pharma Cel Models Ip B V
Publication of PE20160891A1 publication Critical patent/PE20160891A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2016000733A 2013-12-05 2014-12-03 Moduladores de ror gamma (rory) PE20160891A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195813 2013-12-05
EP14183274 2014-09-02

Publications (1)

Publication Number Publication Date
PE20160891A1 true PE20160891A1 (es) 2016-09-24

Family

ID=52021176

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000733A PE20160891A1 (es) 2013-12-05 2014-12-03 Moduladores de ror gamma (rory)

Country Status (29)

Country Link
US (1) US9738600B2 (enExample)
EP (1) EP3077372B8 (enExample)
JP (1) JP6461960B2 (enExample)
KR (1) KR102251128B1 (enExample)
CN (1) CN105980353B (enExample)
AU (1) AU2014359324B2 (enExample)
CA (1) CA2932483C (enExample)
CL (1) CL2016001364A1 (enExample)
CR (1) CR20160303A (enExample)
DK (1) DK3077372T3 (enExample)
DO (1) DOP2016000125A (enExample)
EA (1) EA030393B1 (enExample)
ES (1) ES2722409T3 (enExample)
HR (1) HRP20190483T1 (enExample)
HU (1) HUE043258T2 (enExample)
IL (1) IL246018B (enExample)
LT (1) LT3077372T (enExample)
MX (1) MX368721B (enExample)
MY (1) MY179106A (enExample)
PE (1) PE20160891A1 (enExample)
PH (1) PH12016501066A1 (enExample)
PL (1) PL3077372T3 (enExample)
PT (1) PT3077372T (enExample)
RS (1) RS58650B1 (enExample)
SI (1) SI3077372T1 (enExample)
TN (1) TN2016000224A1 (enExample)
UA (1) UA117941C2 (enExample)
WO (1) WO2015082533A1 (enExample)
ZA (1) ZA201604043B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084784B2 (en) 2014-03-27 2021-08-10 Piramal Enterprises Limited ROR-gamma modulators and uses thereof
SG11201607518RA (en) * 2014-04-16 2016-10-28 Glenmark Pharmaceuticals Sa Aryl and heteroaryl ether compounds as ror gamma modulators
CN107108598B (zh) 2014-10-30 2020-11-17 詹森药业有限公司 作为Rorγt调节剂的噻唑
US9845319B2 (en) 2014-10-30 2017-12-19 Janssen Pharmaceutiuca NV Amide substituted thiazoles as modulators of RORyt
JOP20200117A1 (ar) 2014-10-30 2017-06-16 Janssen Pharmaceutica Nv كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
CN107614062A (zh) 2015-03-12 2018-01-19 加利福尼亚大学董事会 用RORγ抑制剂治疗癌症的方法
CN108026045B (zh) 2015-05-15 2021-04-27 奥瑞基尼探索技术有限公司 用作RORγ调节剂的经过取代的四氢喹啉酮化合物
WO2016193894A1 (en) * 2015-05-29 2016-12-08 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using ror- gamma inhibitors
EP3101005A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101008A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
WO2017010399A1 (ja) * 2015-07-10 2017-01-19 塩野義製薬株式会社 RORγt阻害作用を有する化合物およびそれらを含有する医薬組成物
JP6448867B2 (ja) 2015-12-15 2019-01-09 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag イソインドール化合物
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為RORγT調節劑之6-胺基吡啶-3-基噻唑
WO2018011746A1 (en) 2016-07-14 2018-01-18 Cadila Healthcare Limited Cyclopropyl derivatives as ror-gamma modulators
TW201815388A (zh) * 2016-07-14 2018-05-01 印度商卡迪拉保健有限公司 作為RORγ調節劑之新穎化合物
TWI705958B (zh) 2016-12-05 2020-10-01 荷蘭商領導醫藥控股責任有限公司 RORγ調節子
WO2018116285A1 (en) * 2016-12-23 2018-06-28 Glenmark Pharmaceuticals S.A. Substituted morpholine derivatives as ror gamma modulators
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
EP3790865A1 (en) 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Phenyl substituted pyrazoles as modulators of roryt
JP2021527660A (ja) 2018-06-18 2021-10-14 ヤンセン ファーマシューティカ エヌ.ベー. RORγtのモジュレータとしてのフェニル及びピリジニル置換イミダゾール
ES2928246T3 (es) 2018-06-18 2022-11-16 Janssen Pharmaceutica Nv 6-aminopiridin-3-il pirazoles como moduladores de RORyt
ES2925473T3 (es) 2018-06-18 2022-10-18 Janssen Pharmaceutica Nv Pirazoles de piridinilo como moduladores de RORyt
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
WO2021055376A1 (en) * 2019-09-16 2021-03-25 Dice Alpha, Inc. Il-17a modulators and uses thereof
CN112759541B (zh) * 2019-10-21 2023-03-17 复旦大学 类吲哚衍生物及其用途
CN113072521B (zh) * 2020-01-06 2024-04-05 广东东阳光药业股份有限公司 RORγt抑制剂及其在药物中的应用
TW202136238A (zh) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 RORγt抑制劑及其製備方法和用途
CN114075139B (zh) * 2020-08-14 2025-09-26 广东东阳光药业股份有限公司 五元杂芳环类化合物及其在药物中的应用
CN120383557A (zh) * 2024-01-26 2025-07-29 上海医药集团股份有限公司 一种乙磺酰苯基乙酰胺类化合物的晶型、其制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
KR20150070348A (ko) * 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
JP2016510781A (ja) * 2013-03-15 2016-04-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft RORcモジュレーターとしてのアリールスルファミド及びスルファミン酸誘導体
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators

Also Published As

Publication number Publication date
JP6461960B2 (ja) 2019-01-30
EP3077372A1 (en) 2016-10-12
AU2014359324B2 (en) 2019-02-21
NZ721511A (en) 2020-10-30
PL3077372T3 (pl) 2019-09-30
CA2932483A1 (en) 2015-06-11
CN105980353A (zh) 2016-09-28
IL246018A0 (en) 2016-08-02
PT3077372T (pt) 2019-03-21
TN2016000224A1 (en) 2017-10-06
AU2014359324A1 (en) 2016-07-14
MX368721B (es) 2019-10-14
JP2017504576A (ja) 2017-02-09
ZA201604043B (en) 2017-08-30
LT3077372T (lt) 2019-03-25
US9738600B2 (en) 2017-08-22
EA201691173A1 (ru) 2016-11-30
US20160304448A1 (en) 2016-10-20
EA030393B1 (ru) 2018-07-31
DK3077372T3 (en) 2019-04-23
ES2722409T3 (es) 2019-08-09
EP3077372B8 (en) 2019-04-10
PH12016501066A1 (en) 2016-07-11
CL2016001364A1 (es) 2016-12-02
HRP20190483T1 (hr) 2019-05-17
DOP2016000125A (es) 2016-08-31
UA117941C2 (uk) 2018-10-25
HUE043258T2 (hu) 2019-08-28
CN105980353B (zh) 2019-06-14
EP3077372B1 (en) 2019-02-06
KR20160105413A (ko) 2016-09-06
KR102251128B1 (ko) 2021-05-12
CR20160303A (es) 2016-11-10
CA2932483C (en) 2022-05-17
MY179106A (en) 2020-10-28
IL246018B (en) 2020-01-30
WO2015082533A1 (en) 2015-06-11
SI3077372T1 (sl) 2019-07-31
RS58650B1 (sr) 2019-05-31
MX2016007275A (es) 2017-01-05
BR112016012663A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
PE20160891A1 (es) Moduladores de ror gamma (rory)
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
PE20170268A1 (es) Compuestos de heteroarilo para la inhibicion de cinasa
CY1122610T1 (el) Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
PE20171329A1 (es) Agentes inmunorreguladores
PE20142400A1 (es) Compuestos novedosos
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
PE20200935A1 (es) Compuestos derivados de 2-((bifenil)pirrolidin o piperidin) sulfonamida o carboxamida agonistas de receptores de orexina 2
PE20151794A1 (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
PE20091005A1 (es) N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
PE20211866A1 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
PE20191108A1 (es) Inhibidores selectivos de jak1
UY33779A (es) ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
PE20140381A1 (es) Dispersiones solidas extruidas por fusion que contienen un agente inductor de apoptosis
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PE20080409A1 (es) Compuestos que modulan en el receptor cb2